Hector Alejandro Preti, MD

Associate Professor of Clinical Medicine, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist


Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition
Wen, J, Feng, Y, Huang, W, Chen, H, Liao, B, Rice, L, Preti, HA, Kamble, RT, Zu, Y, Ballon, DJ & Chang, CC 2010, Leukemia Research, vol 34, no. 1, pp. 85-92. DOI:

Prognostic impact of C-REL expression in diffuse large B-cell lymphoma
Curry, CV, Ewton, AA, Olsen, RJ, Logan, BR, Preti, HA, Liu, YC, Perkins, SL & Chang, CC 2009, Journal of Hematopathology, vol 2, no. 1, pp. 20-26. DOI:

Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease
Vega, F, Chang, CC, Schwartz, MR, Preti, HA, Younes, M, Ewton, A, Verm, R & Jaffe, ES 2006, American Journal of Surgical Pathology, vol 30, no. 4, pp. 539-544. DOI:

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
McLaughlin, P, Estey, E, Glassman, A, Romaguera, J, Samaniego, F, Ayala, A, Hayes, K, Maddox, AM, Preti, HA & Hagemeister, FB 2005, Blood, vol 105, no. 12, pp. 4573-4575. DOI:

Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
Dabaja, BS, McLaughlin, P, Ha, CS, Pro, B, Meyers, CA, Seabrooke, LF, Wilder, RB, Kyritsis, AP, Preti, HA, Yung, WKA, Levin, V, Cabanillas, F & Cox, JD 2003, Cancer, vol 98, no. 5, pp. 1021-1028. DOI:

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
Tsimberidou, AM, McLaughlin, P, Younes, A, Rodriguez, MA, Hagemeister, FB, Sarris, A, Romaguera, J, Hess, M, Smith, TL, Yang, Y, Ayala, A, Preti, A, Lee, MS & Cabanillas, F 2002, Blood, vol 100, no. 13, pp. 4351-4357. DOI:

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Younes, A, Preti, HA, Hagemeister, FB, McLaughlin, P, Romaguera, JE, Rodriguez, MA, Samuels, BI, Palmer, JL & Cabanillas, F 2001, Annals of Oncology, vol 12, no. 7, pp. 923-927. DOI:

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma
McLaughlin, P, Hagemeister, FB, Rodriguez, MA, Sarris, AH, Pate, O, Younes, A, Lee, MS, Dang, NH, Romaguera, JE, Preti, AH, McAda, N & Cabanillas, F 2000, Seminars in Oncology, vol 27, no. 6 SUPPL. 12, pp. 37-41.

Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series
López-Guillermo, A, Cabanillas, F, McLaughlin, P, Smith, T, Hagemeister, F, Rodríguez, MA, Romaguera, JE, Younes, A, Sarris, AH, Preti, HA, Pugh, W & Lee, MS 2000, Annals of Oncology, vol 11, no. SUPPL. 1.

Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination
Romaguera, JE, Alma Rodriguez, M, Hagemeister, FB, McLaughlin, P, Rodriguez, J, Preti, A, Younes, A, Sarris, AH & Cabanillas, F 1999, Investigational New Drugs, vol 17, no. 2, pp. 187-192. DOI:

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
Sarris, AH, Kliche, KO, Pethambaram, P, Preti, A, Tucker, S, Jackow, C, Messina, O, Pugh, W, Hagemeister, FB, McLaughlin, P, Rodriguez, MA, Romaguera, J, Fritsche, H, Witzig, T, Duvic, M, Andreeff, M & Cabanillas, F 1999, Annals of Oncology, vol 10, no. 4, pp. 433-440. DOI:

Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
López-Guillermo, A, Cabanillas, F, McDonnell, TI, McLaughlin, P, Smith, T, Pugh, W, Hagemeister, F, Rodríguez, MA, Romaguera, JE, Younes, A, Sarris, AH, Preti, HA & Lee, MS 1999, Blood, vol 93, no. 9, pp. 3081-3087.

Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
Younes, A, Romaguera, J, Mesina, O, Hagemeister, F, Sarris, AH, Rodriguez, MA, Mclaughlin, P, Preti, HA, Bachier, C & Cabanillas, F 1998, British Journal of Haematology, vol 103, no. 3, pp. 678-683. DOI:

Ninety-six-hour paclitaxel infusion with mitoxantrone and Ifosfamide/Mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma
Romaguera, JE, Hagemeister, FB, Mclaughlin, P, Rodriguez, MA, Bachier, C, Preti, H, Sarris, AH, Weber, D, Younes, A & Cabanillas, F 1998, Leukemia and Lymphoma, vol 32, no. 1-2, pp. 97-106.

The clinical significance of molecular response in indolent follicular lymphomas
López-Guillermo, A, Cabanillas, F, McLaughlin, P, Smith, T, Hagemeister, F, Rodríguez, MA, Romaguera, JE, Younes, A, Sarris, AH, Preti, HA, Pugh, W & Lee, MS 1998, Blood, vol 91, no. 8, pp. 2955-2960.

Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-Cell lymphoma: A study of 37 previously untreated patients
Romaguera, JE, Rodríguez Díaz-Pavon, J, Carías, L, Hagemeister, FB, Mclaughlin, P, Rodríguez, MA, Sarris, AH, Younes, A, Preti, A, Bachier, C, Llerena, E & Cabanillas, F 1998, Leukemia and Lymphoma, vol 28, no. 3-4, pp. 295-306.

High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: Mediastinal localization predicts for a favorable outcome
Popat, U, Przepiork, D, Champlin, R, Pugh, W, Amin, K, Mehra, R, Rodriguez, J, Giralt, S, Romaguera, J, Rodriguez, A, Preti, A, Andersson, B, Khouri, I, Claxton, D, de Lima, M, Donato, M, Anderlini, P, Gajewski, J, Cabanillas, F & van Besien, K 1998, Journal of Clinical Oncology, vol 16, no. 1, pp. 63-69.

Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma
Younes, A, Rodriguez, MA, McLaughlin, P, North, L, Sarris, AH, Pate, O, Hagemeister, FB, Romaguera, J, Preti, A, Bachier, C & Cabanillas, F 1997, Leukemia and Lymphoma, vol 26, no. 1-2, pp. 77-82.

Prognostic value of serum interleukin-6 in diffuse large-cell lymphona
Preti, HA, Cabanillas, F, Talpaz, M, Tucker, SL, Seymour, JF & Kurzrock, R 1997, Annals of Internal Medicine, vol 127, no. 3, pp. 186-194.

Paclitaxel (Taxol®) for the treatment of lymphoma
Younes, A, Ayoub, JP, Sarris, A, North, L, Pate, O, McLaughlin, P, Rodriguez, MA, Romaguera, J, Hagemeister, F, Bachier, C, Preti, A & Cabanillas, F 1997, Annals of Oncology, vol 8, no. SUPPL. 1.